Skip to main content
. 2023 Jan 12;11(1):e006136. doi: 10.1136/jitc-2022-006136

Figure 2.

Figure 2

Pan-Immune-Inflammation Value (PIV) at screening was significantly lower in mCRC participants who received clinical benefit (PR+SD) compared with those who did not receive benefit (PD+NE). PIV=Neutrophils×Platelets×Monocytes/Lymphocytes. Median values are indicated by horizontal lines. Data failed Shapiro-Wilk normality test so comparison was performed with Mann-Whitney test (*p<0.05). mCRC, metastatic colorectal cancer; PR, partial response; SD, stable disease; NE, not evaluable.